Tags

Type your tag names separated by a space and hit enter

Automated, multiplex assay for high-frequency microsatellite instability in colorectal cancer.
J Clin Oncol. 2003 Aug 15; 21(16):3105-12.JC

Abstract

PURPOSE

In a series of hereditary nonpolyposis colorectal cancer (HNPCC) patients, we evaluated the sensitivities of the individual microsatellites recommended by the National Cancer Institute (NCI) consensus workshop for detection of high-frequency microsatellite instability (MSI-H). On the basis of this evaluation, we developed a three-marker assay that assigns microsatellite instability (MSI) in a multiplex polymerase chain reaction.

METHODS

Individual marker sensitivity was assessed in 18 HNPCC tumors. Multiplex and NCI assays were then assessed in a series of 120 patients with early-onset colon cancer.

RESULTS

The sensitivity of microsatellite markers BAT25, BAT26, D2S123, D5S346, and D17S250 for ASI in HNPCC cancers was 100%, 94%, 72%, 50%, and 50%, respectively. The three most accurate markers were combined and optimized in a multiplex assay that assigned MSI-H whenever at least two of three markers revealed ASI. In early-onset colon cancers, the prevalence of MSI-H determined by the multiplex assay and by the NCI assay was 16% and 23%, respectively. The additional MSI-H tumors and patients with MSI-H identified by the NCI assay lacked the traits characteristic of MSI-H seen in tumors and patients identified by the multiplex assay: retention of heterozygosity (NCI additional 22% v multiplex 84%; P =.003), characteristic tumor morphology (0% v 64%; P =.006), and 5-year cancer survival rate (44% v 100%; P =.0003).

CONCLUSION

The multiplex assay identifies colon cancers with MSI-H by assessing three highly accurate microsatellite markers. This assay identifies a smaller MSI-H cohort with more homogeneous clinical features and is superior as a marker of favorable prognosis. It merits prospective evaluation as a marker of prognosis and as a screening test for HNPCC.

Authors+Show Affiliations

Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12915601

Citation

Nash, G M., et al. "Automated, Multiplex Assay for High-frequency Microsatellite Instability in Colorectal Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 21, no. 16, 2003, pp. 3105-12.
Nash GM, Gimbel M, Shia J, et al. Automated, multiplex assay for high-frequency microsatellite instability in colorectal cancer. J Clin Oncol. 2003;21(16):3105-12.
Nash, G. M., Gimbel, M., Shia, J., Culliford, A. T., Nathanson, D. R., Ndubuisi, M., Yamaguchi, Y., Zeng, Z. S., Barany, F., & Paty, P. B. (2003). Automated, multiplex assay for high-frequency microsatellite instability in colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 21(16), 3105-12.
Nash GM, et al. Automated, Multiplex Assay for High-frequency Microsatellite Instability in Colorectal Cancer. J Clin Oncol. 2003 Aug 15;21(16):3105-12. PubMed PMID: 12915601.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Automated, multiplex assay for high-frequency microsatellite instability in colorectal cancer. AU - Nash,G M, AU - Gimbel,M, AU - Shia,J, AU - Culliford,A T, AU - Nathanson,D R, AU - Ndubuisi,M, AU - Yamaguchi,Y, AU - Zeng,Z S, AU - Barany,F, AU - Paty,P B, PY - 2003/8/14/pubmed PY - 2003/9/16/medline PY - 2003/8/14/entrez SP - 3105 EP - 12 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J Clin Oncol VL - 21 IS - 16 N2 - PURPOSE: In a series of hereditary nonpolyposis colorectal cancer (HNPCC) patients, we evaluated the sensitivities of the individual microsatellites recommended by the National Cancer Institute (NCI) consensus workshop for detection of high-frequency microsatellite instability (MSI-H). On the basis of this evaluation, we developed a three-marker assay that assigns microsatellite instability (MSI) in a multiplex polymerase chain reaction. METHODS: Individual marker sensitivity was assessed in 18 HNPCC tumors. Multiplex and NCI assays were then assessed in a series of 120 patients with early-onset colon cancer. RESULTS: The sensitivity of microsatellite markers BAT25, BAT26, D2S123, D5S346, and D17S250 for ASI in HNPCC cancers was 100%, 94%, 72%, 50%, and 50%, respectively. The three most accurate markers were combined and optimized in a multiplex assay that assigned MSI-H whenever at least two of three markers revealed ASI. In early-onset colon cancers, the prevalence of MSI-H determined by the multiplex assay and by the NCI assay was 16% and 23%, respectively. The additional MSI-H tumors and patients with MSI-H identified by the NCI assay lacked the traits characteristic of MSI-H seen in tumors and patients identified by the multiplex assay: retention of heterozygosity (NCI additional 22% v multiplex 84%; P =.003), characteristic tumor morphology (0% v 64%; P =.006), and 5-year cancer survival rate (44% v 100%; P =.0003). CONCLUSION: The multiplex assay identifies colon cancers with MSI-H by assessing three highly accurate microsatellite markers. This assay identifies a smaller MSI-H cohort with more homogeneous clinical features and is superior as a marker of favorable prognosis. It merits prospective evaluation as a marker of prognosis and as a screening test for HNPCC. SN - 0732-183X UR - https://www.unboundmedicine.com/medline/citation/12915601/Automated_multiplex_assay_for_high_frequency_microsatellite_instability_in_colorectal_cancer_ L2 - https://ascopubs.org/doi/10.1200/JCO.2003.11.133?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -